I-SPY2 Case Study:
2026-04-30
Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial
Journal of Clinical Oncology · 2026-04-14 · 1 citations
TIP-10. Update on GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma
Neuro-Oncology · 2025-11-01 · 1 citations
Statistical innovations in clinical trial design with a focus on drug combinations, factorials, and other multiple therapy issues
The Journal of Prevention of Alzheimer s Disease · 2025-10-27 · 2 citations
Decoding Neural Signatures of Semantic Evaluation in Depression and Suicidality.
PubMed · 2025-07-30
Adaptive Bayesian Clinical Trials: The Past, Present, and Future of Clinical Research
Journal of Clinical Medicine · 2025-07-25 · 5 citations
Abstract PS9-03: Circulating tumor DNA (ctDNA), dormant disseminated tumor cells (DTCs) and recurrence outcomes in breast cancer survivors on the SURMOUNT Study
Clinical Cancer Research · 2025-06-13 · 2 citations
Update on GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.
Journal of Clinical Oncology · 2025-05-28 · 1 citations
Annual Versus Biennial Mammographic Screening
Journal of Clinical Oncology · 2024-12-17 · 1 citations
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer
Breast Cancer Research and Treatment · 2024-12-03 · 4 citations
Nivolumab in Patients With Advanced or Metastatic Malignancies, Including Rare Cancers: Results of CheckMate 627, an Adaptive Basket Design Clinical Trial
JCO oncology advances. · 2024-11-01 · 3 citations
LTBK-02. EVALUATION OF PAXALISIB IN GBM AGILE PHASE 3 REGISTRATION PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA
Neuro-Oncology · 2024-11-01 · 2 citations
CTNI-39. UPDATE ON GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA
Neuro-Oncology · 2024-11-01 · 1 citations
Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer
Cell Reports Medicine · 2024-11-01 · 9 citations
KS03.5.A EVALUATION OF VAL-083 IN GBM AGILE, A PHASE 3 REGISTRATION PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA
Neuro-Oncology · 2024-10-01
P27.11.A GLOBAL EXPANSION OF GBM AGILE: A PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA
Neuro-Oncology · 2024-10-01
500TiP Update on GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma
Annals of Oncology · 2024-09-01
638P Final results of IMPACT 2, a randomized study evaluating molecular profiling and targeted agents in metastatic cancer at MD Anderson Cancer Center
Annals of Oncology · 2024-09-01 · 1 citations